Lexicon Pharmaceuticals Appoints New Chief Medical Officer
Ticker: LXRX · Form: 8-K · Filed: Nov 20, 2024
Sentiment: neutral
Topics: executive-change, personnel
Related Tickers: LXRX
TL;DR
Lexicon Pharma names Dr. Joseph as new CMO, replacing Dr. Edelman.
AI Summary
Lexicon Pharmaceuticals, Inc. announced on November 19, 2024, the appointment of Dr. Tamara A. Z. Joseph as Chief Medical Officer, effective November 20, 2024. Dr. Joseph previously served as Senior Vice President, Clinical Development at the company. The filing also disclosed the departure of Dr. Jeffrey L. Edelman from his role as Chief Medical Officer.
Why It Matters
The appointment of a new Chief Medical Officer is a significant leadership change that could impact the company's drug development strategy and clinical trial execution.
Risk Assessment
Risk Level: medium — Changes in key executive positions, especially the Chief Medical Officer, can signal shifts in strategic direction or operational focus, warranting close observation.
Key Players & Entities
- Lexicon Pharmaceuticals, Inc. (company) — Registrant
- Dr. Tamara A. Z. Joseph (person) — Appointed Chief Medical Officer
- Dr. Jeffrey L. Edelman (person) — Departing Chief Medical Officer
- November 19, 2024 (date) — Date of Report
- November 20, 2024 (date) — Effective date of appointment
FAQ
What is the effective date of Dr. Joseph's appointment as Chief Medical Officer?
Dr. Joseph's appointment is effective November 20, 2024.
What was Dr. Joseph's previous role at Lexicon Pharmaceuticals?
Dr. Joseph previously served as Senior Vice President, Clinical Development at Lexicon Pharmaceuticals.
Who is replacing Dr. Jeffrey L. Edelman as Chief Medical Officer?
Dr. Tamara A. Z. Joseph is replacing Dr. Jeffrey L. Edelman as Chief Medical Officer.
What is the date of this Form 8-K filing?
The date of this Form 8-K filing is November 19, 2024.
In what state was Lexicon Pharmaceuticals, Inc. incorporated?
Lexicon Pharmaceuticals, Inc. was incorporated in Delaware.
Filing Stats: 1,075 words · 4 min read · ~4 pages · Grade level 11.1 · Accepted 2024-11-20 16:07:25
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 LXRX The Nasdaq Global Select Market
- $50,000 — ors as follows: an annual retainer of $50,000 for service on the board of directors (
- $75,000 — for service on the board of directors ($75,000 for service as non-executive chairman o
- $10,000 — ear of service; an annual retainer of $10,000 for service on the audit committee of t
- $20,000 — it committee of the board of directors ($20,000 for service as chair of the audit commi
- $7,500 — ear of service; an annual retainer of $7,500 for service on the compensation committ
- $15,000 — on committee of the board of directors ($15,000 for service as chair of the compensatio
- $5,000 — of service; and an annual retainer of $5,000 for service on the corporate governance
- $500,000 — gate grant date fair value of more than $500,000 during any calendar year, taken togethe
Filing Documents
- lxrx-20241119.htm (8-K) — 32KB
- pressreleasecheungelection.htm (EX-99.1) — 10KB
- 0001062822-24-000062.txt ( ) — 167KB
- lxrx-20241119.xsd (EX-101.SCH) — 2KB
- lxrx-20241119_lab.xml (EX-101.LAB) — 21KB
- lxrx-20241119_pre.xml (EX-101.PRE) — 12KB
- lxrx-20241119_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 — Press Release of Lexicon Pharmaceuticals, Inc. dated November 20, 2024 EX-104 — Cover Page Interactive Data File (embedded within the Inline XBRL document)
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Lexicon Pharmaceuticals, Inc. Date: November 20, 2024 By: /s/ Brian T. Crum Brian T. Crum Senior Vice President and General Counsel